Navigation Links
Inverness Medical Innovations Completes Acquisition of Matria Healthcare, Inc.
Date:5/9/2008

WALTHAM, Mass., May 9 /PRNewswire-FirstCall/ -- Inverness Medical Innovations (Amex: IMA) today announced that its previously announced acquisition of Matria Healthcare, Inc. was successfully completed and effective prior to the opening of business today, May 9, 2008. Matria, headquartered in Marietta, Georgia, provides comprehensive, integrated health management services particularly in the areas of women's and children's health, cardiology and oncology. The final purchase price consisted of approximately $143.9 million, and approximately 1.8 million shares of Inverness Series B Convertible Perpetual Preferred Stock (Amex: IMA.PR.B). In addition, existing options to purchase Matria stock have been assumed by Inverness and have converted into options to purchase approximately 1.5 million shares of Inverness common stock.

As a result of the merger, Matria's common stock will no longer trade on The NASDAQ Global Select Market. Pursuant to the merger, each outstanding share of Matria common stock, not owned by Matria or its affiliates and not subject to appraisal rights, has been automatically converted into the right to receive (i) $6.50 in cash, without interest, and (ii) a portion of a share of Series B Preferred Stock of Inverness. Inverness expects that the shares of Series B Preferred Stock will begin trading on the American Stock Exchange LLC as of the opening of the market today, May 9, 2008. The listing approval of the American Stock Exchange LLC for the shares of Series B Preferred Stock is contingent upon Inverness being in compliance with all applicable listing standards on the date it begins trading on the Exchange, and may be rescinded if Inverness is not in compliance with such standards.

About Inverness

By developing new capabilities in near-patient diagnosis, monitoring and health management, Inverness Medical Innovations enables individuals to take charge of improving their health and quality of life. A global leader in rapid point-of-care diagnostics, Inverness' products, as well as its new product development efforts, focus on infectious disease, cardiology, oncology, drugs of abuse and women's health. Inverness is headquartered in Waltham, Massachusetts. For additional information on Inverness Medical Innovations, please visit http://www.invernessmedical.com.


'/>"/>
SOURCE Inverness Medical Innovations
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
2. Inverness - Chemogen Establish Exclusive License for TB Antibodies
3. Inverness Medical Innovations Announces Proposed Public Offering of Common Stock
4. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
5. Inverness Medical Innovations Acquires ParadigmHealth
6. Inverness Medical Innovations to Participate at JP Morgan Healthcare Conference on January 8, 2008
7. Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
8. Correction to Press Release Dated January 31, 2008: Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
9. Inverness Medical Innovations Completes Acquisition of BBI Holdings Plc
10. Inverness Medical Innovations Announces Fourth Quarter 2007 Results
11. Inverness Medical Innovations to Participate at Bank of America 2008 Smid Cap Conference on March 26, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... KONG, Feb. 24, 2017 China Cord Blood Corporation ... China,s leading provider of cord blood collection, laboratory testing, ... today announced its unaudited financial results for the third ... ended December 31, 2016. Third Quarter of ... third quarter of fiscal 2017 increased by 18.6% to ...
(Date:2/24/2017)... VWR), the leading global independent provider of product and service ... results for the fourth quarter and full year ended December ... record quarterly net sales of $1.13 billion, up 1.6% year-over-year, ... 4Q16 EMEA-APAC segment net sales increased 0.4%, up ... increased 2.5%, or down 0.9% on an organic basis, driven ...
(Date:2/23/2017)... Financial Highlights (in ... Months Ended December 31,Twelve Months Ended December 31,20162015% ... $           300$     ... Revenue 3539(10)%9498(4)%Kuvan Net Product Revenue ... 756025%297303(2)%Vimizim Net Product Revenue ...
(Date:2/23/2017)... 2017  MIODx announced today that it has ... technologies from the University of California, San Francisco ... monitor a patient for response to immune checkpoint ... second license extends the technology with a method ... have an immune-related adverse event (IRAE) from their ...
Breaking Biology Technology:
(Date:2/8/2017)... AWRE ), a leading supplier of biometrics software ... year ended December 31, 2016. Revenue for ... $6.9 million in the same quarter last year. Operating income ... to $2.6 million in the fourth quarter of 2015. Net ... or $0.02 per diluted share, which compares to $1.8 million, ...
(Date:2/8/2017)... The biometrics market has reached a ... organizations, desires to better authenticate or identify users ... challenge questions), biometrics is quickly working its way ... is driven by use cases, though there traditionally ... uses cases, with consumer-facing use cases encompassing authentication, ...
(Date:2/7/2017)... 2017   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce that the latest ... highly flexible and award winning eClinical solution, is now ... is a proven Software-as-a-Service (SaaS) clinical research technology ... but also delivers an entire suite of eClinical tools ...
Breaking Biology News(10 mins):